BiomX Inc. (PHGE-UN)
USD 0.9
(-5.26%)
USD 0.9
(-5.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.81 Million USD | -8.72% |
| 2022 | -23.65 Million USD | 27.33% |
| 2021 | -32.88 Million USD | -22.39% |
| 2020 | -27.89 Million USD | -23.96% |
| 2019 | -20.18 Million USD | -82.11% |
| 2018 | -12.51 Million USD | -68.82% |
| 2017 | -6.33 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -6.55 Million USD | -204.29% |
| 2024 Q2 | -9.39 Million USD | 133.29% |
| 2023 Q4 | -5.06 Million USD | -1224.61% |
| 2023 Q1 | -5.79 Million USD | -24.3% |
| 2023 FY | - USD | -8.72% |
| 2023 Q3 | -382 Thousand USD | 93.25% |
| 2023 Q2 | -5.65 Million USD | 2.28% |
| 2022 Q3 | -5.58 Million USD | 12.0% |
| 2022 FY | - USD | 27.33% |
| 2022 Q4 | -4.65 Million USD | 16.64% |
| 2022 Q2 | -6.35 Million USD | 10.15% |
| 2022 Q1 | -7.06 Million USD | 21.16% |
| 2021 Q2 | -6.73 Million USD | 16.99% |
| 2021 Q3 | -9.2 Million USD | -36.7% |
| 2021 Q4 | -8.96 Million USD | 2.65% |
| 2021 FY | - USD | -22.39% |
| 2021 Q1 | -8.11 Million USD | 4.6% |
| 2020 Q4 | -8.5 Million USD | -3.38% |
| 2020 Q3 | -8.22 Million USD | -39.96% |
| 2020 FY | - USD | -23.96% |
| 2020 Q1 | -5.46 Million USD | 70.62% |
| 2020 Q2 | -5.87 Million USD | -7.58% |
| 2019 Q1 | -117.18 Thousand USD | -2311.8% |
| 2019 Q4 | -18.6 Million USD | -2905.32% |
| 2019 Q3 | -618.93 Thousand USD | -116.28% |
| 2019 FY | - USD | -82.11% |
| 2019 Q2 | -286.16 Thousand USD | -144.21% |
| 2018 Q1 | -1000.00 USD | 0.0% |
| 2018 Q3 | -650.00 USD | 0.0% |
| 2018 Q4 | 5298.00 USD | 915.08% |
| 2018 FY | - USD | -68.82% |
| 2017 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 27.978% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 42.845% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 55.378% |
| Azitra, Inc. | -10.67 Million USD | -113.76% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -178.912% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -232.469% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 20.227% |
| CEL-SCI Corporation | -27.56 Million USD | 17.219% |
| iBio, Inc. | -14.02 Million USD | -62.72% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 7.755% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -13.044% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 0.044% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -64.431% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -375.313% |
| NanoViricides, Inc. | -7.75 Million USD | -194.118% |
| Oragenics, Inc. | -20.87 Million USD | -9.28% |
| BiomX Inc. | -22.81 Million USD | -0.0% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 295.82% |
| Palatin Technologies, Inc. | -29.03 Million USD | 21.412% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 34.968% |